pcDNA3-IGFBP5-V5 Citations (4)
Originally described in: Johnson Lab PlasmidsUnpublished
Articles Citing pcDNA3-IGFBP5-V5
| Articles |
|---|
| PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma. Hanna JA, Garcia MR, Go JC, Finkelstein D, Kodali K, Pagala V, Wang X, Peng J, Hatley ME. Cell Death Dis. 2016 Jun 9;7(6):e2256. doi: 10.1038/cddis.2016.159. PubMed |
| ERAD-dependent control of the Wnt secretory factor Evi. Glaeser K, Urban M, Fenech E, Voloshanenko O, Kranz D, Lari F, Christianson JC, Boutros M. EMBO J. 2018 Feb 15;37(4). pii: embj.201797311. doi: 10.15252/embj.201797311. Epub 2018 Jan 29. PubMed |
| KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer. Wang W, Lim KG, Feng M, Bao Y, Lee PL, Cai Y, Chen Y, Zhang H, Marzese D, Hoon DSB, Yu Q. Mol Cancer Ther. 2018 Sep;17(9):1973-1983. doi: 10.1158/1535-7163.MCT-17-0802. Epub 2018 Jun 20. PubMed |
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
Huang YH, Klingbeil O, He XY, Wu XS, Arun G, Lu B, Somerville TDD, Milazzo JP, Wilkinson JE, Demerdash OE, Spector DL, Egeblad M, Shi J, Vakoc CR.
Genes Dev. 2018 Jul 1;32(13-14):915-928. doi: 10.1101/gad.314815.118. Epub 2018 Jun 26.
PubMed
Associated Plasmids |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.